

ASX ANNOUNCEMENT

29 December 2021

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 24 December 2021, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) issued 448,145 new fully paid Ordinary Shares (**New Shares**) to Evolution Capital Pty Ltd (**Evolution** or **Underwriter**) raising \$3,585,160. The issue of New Shares is as a result of the underwriter, in conjunction with sub-underwriters taking-up, all share entitlements attached to the shortfall in the exercise of the former listed Options (ASX:AVRO) exercisable at \$8.00 each on or before 5:00 p.m. (AEST) on 18 December 2021.

Details of the securities issued

Class of securities:	Fully paid ordinary shares
ASX code:	AVR
Date of the issue:	24 December 2021
Total number of securities issued:	448,145

Anteris gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**)¹ that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

¹ As modified by ASIC Instrument 21-0248 dated 7 April 2021 which extends the period of 5 days referred to in section 708A(5)(b) of the Corporations Act to 6 days in respect of shares issued by Anteris.



Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Hannah Howlett

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

